Kailera Therapeutics Inc. research snapshot
KLRA AI stock analysis currently views Kailera Therapeutics as a high-risk, high-reward clinical-stage biopharmaceutical company developing a diversified pipeline of GLP-1 based obesity therapies. The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the latest verified close was $17.32, market capitalization was about $2.24 billion, and the central question is whether Kaileras injectable and oral obesity candidates can overcome tolerability concerns, complete late-stage trials, gain FDA approval, and compete against Novo Nordisk and Eli Lilly. This is informational research and not investment advice.
Current price
$17.32
Market cap
$2.24 billion
AI score
45 / 100
Rating
High-risk clinical-stage biotech with a broad GLP-1 obesity pipeline, pre-revenue and unprofitable
Trend status
Near its 52-week low after a Phase 3 KAI-7535 readout that showed strong efficacy but high nausea and vomiting rates; the stock trades just above the $16 IPO price
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Kailera operates as a clinical-stage biotech developing four GLP-1 based obesity candidates across injectable, oral, and small molecule formats, licensed from Hengrui Pharma for markets outside Greater China. The business has no revenue and no approved products. | Low |
| Moat | The moat is early-stage and unproven. Patent protection on the licensed mechanisms may help, but competition from Novo Nordisk, Lilly, Pfizer, and dozens of clinical-stage peers is intense, and oral small molecule tolerability looks like a real risk after the KAI-7535 readout. | Low |
| Management | CEO Ron Renaud is a biopharma veteran, and the team has executed a strong IPO and moved multiple programs into late-stage trials quickly. The leadership team expanded in 2026 with new board members and a Chief Corporate Affairs Officer. The track record is still short given the company was founded in 2024. | Low |
| Financial trend | Kailera is pre-revenue and unprofitable. Q1 2026 net loss was $78.9 million versus $18.0 million a year earlier, and TTM net loss is about $209.84 million. Cash, equivalents, and marketable securities were $581.9 million at March 31, 2026, before the IPO proceeds of $718.8 million were added, which management says funds operations into mid-2028. | Medium |
| Valuation | At roughly $2.24 billion market cap with pro-forma net cash around $1.2 billion, the market assigns roughly $1.0 billion to the pipeline. For a pre-revenue biotech with multiple Phase 3 programs, this is not obviously cheap or expensive. The outcome depends on clinical, regulatory, and commercial execution. | Medium-low |
| Technical trend | KLRA trades within a $16.39 to $28.23 52-week range and is near the low end after selling off following the Phase 3 KAI-7535 data. The stock is close to the $16 IPO price. Volume spiked on the data release and subsequent analyst commentary. | Medium |
| Risk level | Very high. Key risks include tolerability concerns in oral candidates, clinical trial failures, FDA regulatory hurdles, intense competition from established obesity drug leaders, future financing needs beyond mid-2028, dependence on the Hengrui partnership, and typical clinical-stage biotech volatility. | High |
| AI confidence | Low confidence overall. Business quality, moat, and management assessments rely on limited public information, while financial and market data are more reliable. The value of KLRA depends on clinical outcomes and tolerability that no AI can predict. | Low data confidence |
| Investment certainty | Very low. KLRA is a binary-outcome biotech investment. Pipeline and commercial success could lead to multiples of the current price, while a clinical or regulatory setback could render the stock nearly worthless. | Very low |
KLRA AI stock forecast
The KLRA AI stock forecast uses scenario ranges around the $17.32 cutoff. It does not claim that AI can predict a specific future price. The bullish case requires successful Phase 3 programs for ribupatide injection and oral, improved tolerability for KAI-7535, FDA approvals, and commercial execution in the obesity market. The base case assumes partial pipeline success with partnerships or licensing deals. The bearish case assumes clinical setbacks, tolerability failures, or competitive displacement.
$40 to $60
More likely if the KaiNETIC Phase 3 program for ribupatide injection reads out positive in 2028, ribupatide oral enters global Phase 3 and confirms its China Phase 2 efficacy, KAI-7535 tolerability improves in the global Phase 2 trial, and the company secures FDA approval or a lucrative partnership. Analyst targets from $48 to $57 support this range.
$15 to $30
More likely if clinical data is mixed, approval timelines extend, the company needs additional financing after mid-2028, and competition from established players limits market share expectations. The consensus price target of $42.60 sits above the top of this range, reflecting that most analysts remain positive.
$8 to $15
More likely if KAI-7535 or other candidates face clinical holds, GI tolerability issues limit dosing, FDA rejects filings, cash runs low before milestones are reached, or Novo Nordisk and Eli Lilly maintain dominant positions that limit commercial viability.
KLRA AI technical analysis
KLRA AI technical analysis starts from the $17.32 close on August 3, 2026 used for this August 4 static page. KLRA is a recently public biotech with only a few months of price history and shows very high volatility. The stock is near its 52-week low after the post-data sell-off, trading just above the $16 IPO price. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $17.32 | Latest verified close as of the August 4, 2026 data cutoff. |
| Near support | $16.39 to $16 | The 52-week low is $16.39 with the $16 IPO price just below. A move toward this zone signals continued post-data weakness. |
| Secondary support | $14 to $15 | A break below the IPO price around $16 would open a move toward the low teens. |
| Near resistance | $20 to $23 | The July breakdown area. A recovery above $23 would signal that the post-Phase 3 sell-off has been absorbed. |
| 200-day moving average | Not established | KLRA IPOed in April 2026 and has not been public long enough to have a meaningful 200-day moving average. |
| Momentum | Bearish, RSI near oversold | The stock has been in a downtrend since July and momentum is weak after the data-driven sell-off. |
| Volume | About 350,000 to 950,000 shares daily | Volume spiked on the Phase 3 data release and analyst commentary. Sustained above-average volume near support would signal institutional interest. |
| Volatility | Very high | Clinical-stage biotechs routinely move 10% to 20% on trial data or regulatory news. Position sizing should reflect this. |
| Invalidation | Close below $16.39 or above $23 | A close below the 52-week low at $16.39 would be technically bearish. A breakout above $23 with volume would signal renewed momentum. |
KLRA AI trading strategy
The KLRA AI trading strategy is a rules-based framework, not personalized advice. It accounts for the binary-risk nature of clinical-stage biotech investing, the very high volatility, the stock being near its IPO price, and news-driven price action around data readouts and regulatory updates.
Position around known catalysts: the next earnings report on August 23, 2026, Phase 2 and Phase 3 data readouts for ribupatide and KAI-7535, FDA interactions, and financing announcements. Enter only after understanding the specific trial endpoints, tolerability data, and competitive context.
Clinical-stage biotech positions carry binary risk. Define a max loss of 15% to 20% and size the position so that a complete loss does not materially affect the portfolio. Avoid holding through major data events without a predefined reaction plan.
After major data readouts, wait 2 to 3 sessions for the initial volatility to settle. If data is positive on both efficacy and tolerability and the stock holds above support, a measured trend position may be considered.
Buying on negative data reactions (hoping for reversal) is especially risky for clinical-stage names. Confirm the data quality and tolerability profile yourself from the press release, not just the stock price reaction.
Track clinical trial timelines and tolerability readouts for KAI-9531, KAI-7535, and KAI-4729, cash runway, partnership or licensing announcements, FDA feedback, competitor clinical data, and analyst coverage changes.
Reduce or exit the position if cash runway drops below 12 months without a clear financing plan, if a competing drug shows clearly better efficacy or tolerability, or if clinical holds are announced.
Investment research summary
Kailera Therapeutics is developing a diversified pipeline of GLP-1 based obesity treatments spanning injectable dual agonists, an oral dual agonist, an oral small molecule, and an injectable tri-agonist, licensed from Hengrui Pharma for development outside Greater China.
The moat is speculative. Patent protection on the licensed mechanisms may provide some defensibility, but the company faces dominant incumbents with approved products, deeper pockets, and established commercial infrastructure. The KAI-7535 Phase 3 data showed high nausea and vomiting rates, which raises questions about oral candidate competitiveness.
The thesis fails if KAI-7535 or other candidates show insufficient efficacy or concerning GI tolerability in late-stage trials, if FDA requires additional studies delaying approval, if Novo Nordisk and Eli Lilly maintain pricing power that limits market access, or if the company needs dilutive financing after mid-2028.
Founded in 2024 and led by CEO Ron Renaud, a biopharma veteran, Kailera closed a $718.8 million IPO in April 2026 and has moved multiple programs into late-stage trials quickly. The team is small (145 employees) and the long-term track record is still being written.
The obesity treatment market is undergoing a paradigm shift with GLP-1 receptor agonists showing unprecedented efficacy, and the global obesity drug market is projected to be massive. However, competition is intensifying rapidly as multiple players advance similar mechanisms, and tolerability is emerging as a key differentiator.
At roughly $2.24 billion market cap with pro-forma net cash around $1.2 billion, the enterprise is valued at about $1.0 billion for a pre-revenue pipeline. The margin of safety is minimal given the binary nature of clinical-stage biotech investing. Success could yield substantial returns, while failure could mean near-total loss.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| KLRA price | $17.32 close on August 3, 2026 | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| Market capitalization | $2.24 billion, verified as $17.32 x 129.57M shares via financial_rigor.py | StockAnalysis.com and financial_rigor.py verification | August 4, 2026 |
| Shares outstanding | 129.57 million | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| 52-week range | $16.39 to $28.23 | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| IPO (April 2026) | $16.00 per share, opened at $26, gross proceeds of $718.8 million | Kailera IPO press release and Reuters | August 4, 2026 |
| Revenue (TTM) | $0 (pre-revenue) | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| Net loss (TTM) | -$209.84 million | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| Q1 FY26 net loss | -$78.9 million vs -$18.0 million in Q1 FY25 | Kailera Q1 2026 financial results (GlobeNewswire) | August 4, 2026 |
| Cash (March 31, 2026) | $581.9 million in cash, equivalents, and marketable securities before IPO proceeds | Kailera Q1 2026 financial results (GlobeNewswire) | August 4, 2026 |
| Cash runway | Management guidance says cash including IPO proceeds funds operations into mid-2028 | Kailera Q1 2026 financial results (GlobeNewswire) | August 4, 2026 |
| Diluted EPS (TTM) | -$1.78 | Yahoo Finance | August 4, 2026 |
| FY2026 consensus estimates | Net loss -$466.90 million; EPS -$3.97; free cash flow -$478.33 million | S&P Global Market Intelligence via StockAnalysis.com | August 4, 2026 |
| Analyst target (consensus) | $42.60 average (6 analysts, Strong Buy), range $30 to $57 | S&P Global Market Intelligence via StockAnalysis.com | August 4, 2026 |
| KAI-7535 Phase 3 HARBOR-1 (July 7, 2026) | Up to 10.9% mean weight loss at Week 44 and 11.1% at Week 50; nausea in 70% and vomiting in 67% to 69% of treated participants | Kailera press release (GlobeNewswire, July 7, 2026) | August 4, 2026 |
| Employees | 145 | StockAnalysis.com (S&P Global Market Intelligence) | August 4, 2026 |
| Next earnings date | August 23, 2026 (estimated) | StockAnalysis.com | August 4, 2026 |
This KLRA AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Clinical-stage biotechnology investments carry a risk of total loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
